The prognostic value of syndecan-1 in ovarian cancer patients with long-term follow up

Clinical Ovarian Cancer

Volumn 4, Issue 1, 2011, Pages 12-18

  Madsen, Christine Vestergaard ^a,b   Steffensen, Karina Dahl ^a,b   Waldstrøm, Marianne ^a   Jakobsen, Anders ^a,b  

^a LILLEBAELT HOSPITAL   (Denmark)

^b UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

Author keywords

CD 138; Immunohistochemistry; Ovarian cancer; Prognosis; Syndecan 1

Indexed keywords

SYNDECAN 1;

ADULT; AGED; ARTICLE; CANCER PATIENT; CANCER SURVIVAL; CLINICAL PROTOCOL; CONTROLLED STUDY; EPITHELIUM CELL; FEMALE; FOLLOW UP; GENE EXPRESSION; HAZARD RATIO; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; LONG TERM CARE; MAJOR CLINICAL STUDY; MULTIVARIATE ANALYSIS; OVARY ADENOCARCINOMA; OVARY CARCINOMA; OVERALL SURVIVAL; PROGNOSIS; STROMA CELL; TISSUE MICROARRAY; UNIVARIATE ANALYSIS;

EID: 80052510077     PISSN: 19414390     EISSN: 19414404     Source Type: Journal    
DOI: 10.1016/j.cloc.2011.04.012     Document Type: Article

References (59)

1. A. Jemal, R. Siegel, and J. Xu Cancer statistics, 2010 CA Cancer J Clin 60 2010 277 300
2. J.T. Thigpen Chemotherapy for advanced ovarian cancer: overview of randomized trials Semin Oncol 27 2000 11 16 (Pubitemid 30643847)
3. R.F. Ozols, B.N. Bundy, and B.E. Greer Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study J Clin Oncol 21 2003 3194 3200 (Pubitemid 46606249)
4. M. Harries, and M. Gore Part II: chemotherapy for epithelial ovarian cancer-treatment of recurrent disease Lancet Oncol 3 2002 537 545 (Pubitemid 34993641)
5. A.N. Gordon, J.T. Fleagle, and D. Guthrie Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan J Clin Oncol 19 2001 3312 3322 (Pubitemid 32642183)
6. M. Bernfield, M. Gotte, and P.W. Park Functions of cell surface heparan sulfate proteoglycans Annu Rev Biochem 68 1999 729 777 (Pubitemid 29449208)
7. D.M. Beauvais, and A.C. Rapraeger Syndecans in tumor cell adhesion and signaling Reprod Biol Endocrinol 2 2004 3
8. S. Saunders, and M. Bernfield Cell surface proteoglycan binds mouse mammary epithelial cells to fibronectin and behaves as a receptor for interstitial matrix J Cell Biol 106 1988 423 430 (Pubitemid 18052190)
9. M.J. Stanley, B.F. Liebersbach, and W. Liu Heparan sulfate-mediated cell aggregation Syndecans-1 and -4 mediate intercellular adhesion following their transfection into human B lymphoid cells J Biol Chem 270 1995 5077 5083
10. R.C. Casey, T.R. Oegema Jr., and K.M. Skubitz Cell membrane glycosylation mediates the adhesion, migration, and invasion of ovarian carcinoma cells Clin Exp Metastasis 20 2003 143 152 (Pubitemid 36403279)
11. C.Y. Fears, and A. Woods The role of syndecans in disease and wound healing Matrix Biol 25 2006 443 456 (Pubitemid 44512121)
12. R. Kokenyesi Ovarian carcinoma cells synthesize both chondroitin sulfate and heparan sulfate cell surface proteoglycans that mediate cell adhesion to interstitial matrix J Cell Biochem 83 2001 259 270 (Pubitemid 32896596)
13. M. Kato, S. Saunders, and H. Nguyen Loss of cell surface syndecan-1 causes epithelia to transform into anchorage-independent mesenchyme-like cells Mol Biol Cell 6 1995 559 576
14. D.J. Carey Syndecans: multifunctional cell-surface co-receptors Biochem J 327 Pt 1 1997 1 16 (Pubitemid 27455453)
15. A.C. Rapraeger, A. Krufka, and B.B. Olwin Requirement of heparan sulfate for bFGF-mediated fibroblast growth and myoblast differentiation Science 252 1991 1705 1708 (Pubitemid 21917092)
16. A. Yayon, M. Klagsbrun, and J.D. Esko Cell surface, heparin-like molecules are required for binding of basic fibroblast growth factor to its high affinity receptor Cell 64 1991 841 848 (Pubitemid 121001170)
17. D.M. Ornitz, A. Yayon, and J.G. Flanagan Heparin is required for cell-free binding of basic fibroblast growth factor to a soluble receptor and for mitogenesis in whole cells Mol Cell Biol 12 1992 240 247
18. M. Rusnati, and M. Presta Interaction of angiogenic basic fibroblast growth factor with endothelial cell heparan sulfate proteoglycans Biological implications in neovascularization Int J Clin Lab Res 26 1996 15 23
19. R. Steinfeld, B.H. Van Den, and G. David Stimulation of fibroblast growth factor receptor-1 occupancy and signaling by cell surface-associated syndecans and glypican J Cell Biol 133 1996 405 416 (Pubitemid 26132538)
20. O. Saksela, D. Moscatelli, and A. Sommer Endothelial cell-derived heparan sulfate binds basic fibroblast growth factor and protects it from proteolytic degradation J Cell Biol 107 1988 743 751
21. P.W. Derksen, R.M. Keehnen, and L.M. Evers Cell surface proteoglycan syndecan-1 mediates hepatocyte growth factor binding and promotes Met signaling in multiple myeloma Blood 99 2002 1405 1410 (Pubitemid 34547098)
22. H. Gitay-Goren, S. Soker, and I. Vlodavsky The binding of vascular endothelial growth factor to its receptors is dependent on cell surface-associated heparin-like molecules J Biol Chem 267 1992 6093 6098
23. A. Purushothaman, T. Uyama, and F. Kobayashi Heparanase-enhanced shedding of syndecan-1 by myeloma cells promotes endothelial invasion and angiogenesis Blood 115 2010 2449 2457
24. G.R. Johnson, and L. Wong Heparan sulfate is essential to amphiregulin-induced mitogenic signaling by the epidermal growth factor receptor J Biol Chem 269 1994 27149 27154 (Pubitemid 24332922)
25. E. Feyzi, F. Lustig, and G. Fager Characterization of heparin and heparan sulfate domains binding to the long splice variant of platelet-derived growth factor A chain J Biol Chem 272 1997 5518 5524 (Pubitemid 27102374)
26. R. Garcia-Olivas, J. Hoebeke, and S. Castel Differential binding of platelet-derived growth factor isoforms to glycosaminoglycans Histochem Cell Biol 120 2003 371 382 (Pubitemid 38005356)
27. F. Lustig, J. Hoebeke, and C. Simonson Processing of PDGF gene products determines interactions with glycosaminoglycans J Mol Recognit 12 1999 112 120 (Pubitemid 29178086)
28. G. Cizmeci-Smith, R.C. Stahl, and L.J. Showalter Differential expression of transmembrane proteoglycans in vascular smooth muscle cells J Biol Chem 268 1993 18740 18747 (Pubitemid 23273818)
29. K. Elenius, A. Maatta, and M. Salmivirta Growth factors induce 3T3 cells to express bFGF-binding syndecan J Biol Chem 267 1992 6435 6441
30. K. Hayashi, M. Hayashi, and M. Jalkanen Immunocytochemistry of cell surface heparan sulfate proteoglycan in mouse tissues A light and electron microscopic study J Histochem Cytochem 35 1987 1079 1088
31. C.W. Kim, O.A. Goldberger, and R.L. Gallo Members of the syndecan family of heparan sulfate proteoglycans are expressed in distinct cell-, tissue-, and development-specific patterns Mol Biol Cell 5 1994 797 805 (Pubitemid 24254349)
32. R.D. Sanderson, P. Lalor, and M. Bernfield B lymphocytes express and lose syndecan at specific stages of differentiation Cell Regul 1 1989 27 35
33. M. Barbareschi, P. Maisonneuve, and D. Aldovini High syndecan-1 expression in breast carcinoma is related to an aggressive phenotype and to poorer prognosis Cancer 98 2003 474 483 (Pubitemid 36885986)
34. M. Leivonen, J. Lundin, and S. Nordling Prognostic value of syndecan-1 expression in breast cancer Oncology 67 2004 11 18 (Pubitemid 39370345)
35. C. Seidel, A. Sundan, and M. Hjorth Serum syndecan-1: a new independent prognostic marker in multiple myeloma Blood 95 2000 388 392 (Pubitemid 30041645)
36. R. Lovell, J.A. Dunn, and G. Begum Soluble syndecan-1 level at diagnosis is an independent prognostic factor in multiple myeloma and the extent of fall from diagnosis to plateau predicts for overall survival Br J Haematol 130 2005 542 548 (Pubitemid 43899757)
37. H. Joensuu, A. Anttonen, and M. Eriksson Soluble syndecan-1 and serum basic fibroblast growth factor are new prognostic factors in lung cancer Cancer Res 62 2002 5210 5217 (Pubitemid 35024592)
38. H. Kim, D.S. Choi, and S.J. Chang The expression of syndecan-1 is related to the risk of endometrial hyperplasia progressing to endometrial carcinoma J Gynecol Oncol 21 2010 50 55
39. M. Fujiya, J. Watari, and T. Ashida Reduced expression of syndecan-1 affects metastatic potential and clinical outcome in patients with colorectal cancer Jpn J Cancer Res 92 2001 1074 1081 (Pubitemid 33041176)
40. A. Anttonen, M. Kajanti, and P. Heikkila Syndecan-1 expression has prognostic significance in head and neck carcinoma Br J Cancer 79 1999 558 564 (Pubitemid 29046236)
41. P. Inki, H. Joensuu, and R. Grenman Association between syndecan-1 expression and clinical outcome in squamous cell carcinoma of the head and neck Br J Cancer 70 1994 319 323 (Pubitemid 24247157)
42. A. Matsumoto, M. Ono, and Y. Fujimoto Reduced expression of syndecan-1 in human hepatocellular carcinoma with high metastatic potential Int J Cancer 74 1997 482 491 (Pubitemid 27486504)
43. A. Anttonen, P. Heikkil, and M. Kajanti High syndecan-1 expression is associated with favourable outcome in squamous cell lung carcinoma treated with radical surgery Lung Cancer 32 2001 297 305 (Pubitemid 32487690)
44. R. Miturski, M. Jalkanen, and K. Postawski Immunohistochemical expression of syndecan-1 in human endometrial cancer cells Int J Mol Med 2 1998 397 401
45. M. Lundin, S. Nordling, and J. Lundin Epithelial syndecan-1 expression is associated with stage and grade in colorectal cancer Oncology 68 2005 306 313 (Pubitemid 41160958)
46. J.P. Wiksten, J. Lundin, and S. Nordling Epithelial and stromal syndecan-1 expression as predictor of outcome in patients with gastric cancer Int J Cancer 95 2001 1 6
47. Hasengaowa, J. Kodama, and T. Kusumoto Prognostic significance of syndecan-1 expression in human endometrial cancer Ann Oncol 16 2005 1109 1115 (Pubitemid 41418313)
48. A. Juuti, S. Nordling, and J. Lundin Syndecan-1 expressiona novel prognostic marker in pancreatic cancer Oncology 68 2005 97 106 (Pubitemid 41158964)
49. E.J. Davies, F.H. Blackhall, and J.H. Shanks Distribution and clinical significance of heparan sulfate proteoglycans in ovarian cancer Clin Cancer Res 10 2004 5178 5186 (Pubitemid 39099793)
50. L. Helpman, B.Z. Katz, and T. Safra Systematic antigenic profiling of hematopoietic antigens on ovarian carcinoma cells identifies membrane proteins for targeted therapy development Am J Obstet Gynecol 201 2009 196 197
51. R. Salani, I. Neuberger, and R.J. Kurman Expression of extracellular matrix proteins in ovarian serous tumors Int J Gynecol Pathol 26 2007 141 146 (Pubitemid 46573209)
52. T. Kusumoto, J. Kodama, and N. Seki Clinical significance of syndecan-1 and versican expression in human epithelial ovarian cancer Oncol Rep 23 2010 917 925
53. A. Jakobsen, K. Bertelsen, and J.E. Andersen Dose-effect study of carboplatin in ovarian cancer: a Danish Ovarian Cancer Group study J Clin Oncol 15 1997 193 198 (Pubitemid 27020573)
54. Y. Shimizu, S. Kamoi, and S. Amada Toward the development of a universal grading system for ovarian epithelial carcinoma: testing of a proposed system in a series of 461 patients with uniform treatment and follow-up Cancer 82 1998 893 901 (Pubitemid 28104169)
55. K.D. Steffensen, M. Waldstrom, and U. Jeppesen Prediction of response to chemotherapy by ERCC1 immunohistochemistry and ERCC1 polymorphism in ovarian cancer Int J Gynecol Cancer 18 2008 702 710 (Pubitemid 352020157)
56. K.A. Olaussen, A. Dunant, and P. Fouret DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy N Engl J Med 355 2006 983 991 (Pubitemid 44343542)
57. N. Kambham, C. Kong, and T.A. Longacre Utility of syndecan-1 (CD138) expression in the diagnosis of undifferentiated malignant neoplasms: a tissue microarray study of 1,754 cases Appl Immunohistochem Mol Morphol 13 2005 304 310 (Pubitemid 41697391)
58. D.G. Rosen, X. Huang, and M.T. Deavers Validation of tissue microarray technology in ovarian carcinoma Mod Pathol 17 2004 790 797 (Pubitemid 38843361)
59. S. Selvarajan, S.Y. Tan, and L.H. Sii c-erbB-2 (HER-2/neu) immunohistochemistry in invasive breast cancer: is there concordance between standard sections and tissue microarrays? Pathology 38 2006 316 320 (Pubitemid 44266629)